Sanofi under pressure following long-awaited biosimilar launch.
Tissue engineering product previously flopped in EU.
Reports suggest Sanofi could pay $30 billion for Swiss biotech.
Encouraging data could point to strong outcomes data, expected next year
How pharma can move on from the recent controversies around pricing is one of the industry’s biggest issues.
Sales of cancer drug Ibrance also fall short of expectations.
FDA has concerns over Sanofi manufacturing plant.
Drug could earn $2.8 billion if approved in AD and asthma
A round-up of this week’s top digital healthcare news. Marco Ricci reports.
